Disseminated tuberculosis after anti-TNFα treatment

Lancet

Volumn 369, Issue 9556, 2007, Pages 162-

  Malipeddi, Aruna S ^a   Rajendran, Rajesh ^a   Kallarackal, George ^a  

^a KETTERING GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DYSPNEA; FEMALE; HUMAN; INFECTION RISK; LABORATORY TEST; LIVER BIOPSY; MILIARY TUBERCULOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33846081942     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60078-6     Document Type: Article

References (5)

1. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Thorax 60 (2005) 800-805
2. Keane J., Gershon S., Wise R., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α neutralizing agent. N Engl J Med 345 (2001) 1098-1104
3. Mohan A., Cote T., Block J., Manadan A., Siegel J., and Braun M. Tuberculosis following the use of etanercept, a tumour necrosis factor inhibitor. Clin Infect Dis 39 (2004) 295-299
4. Schiff M., Burmester G., Kent J., et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
5. Ferrara G., Losi M., D'Amico R., Roversi P., et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367 (2006) 1328-1334